References
- Blum J, Handmaker H, Lister-James J, Rinne N, and the NeoTect Solitary Pulmonary Nodule Study Group. A multicenter trial with a somatostatin analog 99m-Tc Depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117: 1232–8.
- Danielsson RB AA.th M, Kölbeck KG, Klominek J, Svensson J. Accumulation of 99m-Tc-Depreotide (Neo-spect) in axillary sweat glands. Clin Nucl Med 2003; 28:789–90.
- Goldsmith SJ, Kostakoglu L. Nuclear medicine imaging of lung cancer. Radiol Clin North Am 2000;38:511–24.
- Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Sem Nucl Med 2002;32:84–91.
- Reubi JC, Laissue J, Krenning EP, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical applica-tions. J Steroid Biochem Molec Biol 1992;43:27–35.
- Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002;43:752–6.
- Shih WJ, Hirschowitz E, Bensadoun E, Woodring J, Ryo YU, Kraman S. Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies. Ann Nucl Med 2002;16:213–9.
- Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998;58:1850–9.